Cabotegravir/rilpivirine (Cabenuva) vs Elvitegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Cabotegravir/rilpivirine (Cabenuva)
Marketed by GlaxoSmithKline
NCT05917509 · Phase 3 · completed
The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT06411223 (registry estimate)
Reported efficacy
Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)
Result source: NCT03299049
Elvitegravir · Stribild
Marketed by Gilead Sciences and partners
NCT01095796 · Phase 3 · completed
Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.
Reported efficacy
The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)
Result source: NCT01095796
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cabotegravir/rilpivirine (Cabenuva) | Elvitegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352125 other results
| 87.6% vs 84.1%vs AtriplaNCT0109579634 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 0%vs DTG + RPVNCT03639311 | —Not reported |
| CD4 count, change (week 48) | 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT0212035236 other results
| 295 vs 273vs AtriplaNCT0109579626 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352
125 other results
- 95% vs 91% NCT02120352
- 80% vs 71% NCT01641809
- 87% vs 71% NCT01641809
- 80% vs 71% NCT01641809
- 65% vs 0% NCT01641809
- 67% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 67% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 73% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 72% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 75% vs 63% NCT01641809
- 62% vs 0% NCT01641809
- 85% vs 83% NCT01641809
- 75% vs 68% NCT01641809
- 60% vs 0% NCT01641809
- 85% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 52% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 83% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 91% vs 94% NCT01641809
- 82% vs 68% NCT01641809
- 92% vs 89% NCT01641809
- 82% vs 71% NCT01641809
- 92% vs 94% NCT01641809
- 80% vs 69% NCT01641809
- 91% vs 91% NCT01641809
- 78% vs 69% NCT01641809
- 89% vs 91% NCT01641809
- 75% vs 66% NCT01641809
- 85% vs 87% NCT01641809
- 85% vs 74% NCT01641809
- 94% vs 96% NCT01641809
- 74% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 84% vs 63% NCT01641809
- 74% vs 0% NCT01641809
- 93% vs 83% NCT01641809
- 85% vs 68% NCT01641809
- 70% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 70% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 87% vs 71% NCT01641809
- 96% vs 94% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 95% vs 94% NCT01641809
- 87% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 95% vs 91% NCT01641809
- 85% vs 66% NCT01641809
- 95% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 96% vs 96% NCT01641809
- 57% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 55% vs 0% NCT01641809
- 57% vs 0% NCT01641809
- 55% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 53% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 53% vs 0% NCT01641809
- 68% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 68% vs 63% NCT01641809
- 50% vs 0% NCT01641809
- 79% vs 83% NCT01641809
- 72% vs 68% NCT01641809
- 52% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 72% vs 68% NCT01641809
- 52% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 78% vs 68% NCT01641809
- 90% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 92% vs 94% NCT01641809
- 83% vs 68% NCT01641809
- 96% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 98% vs 94% NCT01641809
- 83% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 98% vs 91% NCT01641809
- 78% vs 66% NCT01641809
- 90% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 96% vs 96% NCT01641809
- 98% vs 100% NCT03639311
- Elvitegravir
- 87.6% vs 84.1%vs AtriplaNCT01095796
34 other results
- 91.6% vs 88.5% NCT01797445
- 87.2% vs 80.8% NCT01705574
- 93.1% vs 92.8% NCT01780506
- 59% vs 57.8% NCT00708162
- 93.8% vs 87.1% NCT01475838
- 93.4% vs 88.1% NCT01495702
- 89.5% vs 86.8% NCT01106586
- 80.2% vs 75.3% NCT01095796
- 86.9% vs 83.1% NCT01780506
- 77.6% vs 74.6% NCT01106586
- 84.2% vs 81.5% NCT01095796
- 92.8% vs 89.1% NCT01815736
- 84% vs 82.3% NCT01797445
- 89.2% vs 88.2% NCT01780506
- 47.6% vs 45% NCT00708162
- 52.4% vs 53% NCT00708162
- 53.6% vs 56.4% NCT00708162
- 86.9% vs 69.8% NCT01475838
- 86.6% vs 80.4% NCT01495702
- 83.3% vs 82.3% NCT01106586
- 85.9% vs 83.2% NCT01095796
- 88.8% vs 85.5% NCT01095796
- 59.8% vs 57.5% NCT00708162
- 61% vs 60.7% NCT00708162
- 86.1% vs 84.8% NCT01106586
- 91.5% vs 88.5% NCT01106586
- 76.1% vs 78.1% NCT01095796
- 78.4% vs 73.1% NCT01106586
- 88.4% vs 89.7% NCT01497899
- 89.6% vs 87% NCT00869557
- 88.4% vs 87.9% NCT01497899
- 89.6% vs 87% NCT00869557
- 91.7% vs 82.6% NCT00869557
- 89.6% vs 87% NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 0% vs 0%vs DTG + RPVNCT03639311
- Elvitegravir
- —Not reported
CD4 count, change (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT02120352
36 other results
- 263.7 vs 346.1 NCT02120352
- 257.5 vs 369.9 NCT02120352
- 264.4 vs 346.1 NCT02120352
- 267.5 vs 281.7 NCT01641809
- 287 vs 279.4 NCT01641809
- 201.4 vs 257.1 NCT01641809
- 269.4 vs 263.8 NCT01641809
- 241.6 vs 262.5 NCT01641809
- 212.8 vs 221.5 NCT01641809
- 213 vs 185.2 NCT01641809
- 205.2 vs 197.4 NCT01641809
- 188.1 vs 178.2 NCT01641809
- 177.7 vs 166.4 NCT01641809
- 180.9 vs 143.4 NCT01641809
- 286.2 vs 281.7 NCT01641809
- 278.1 vs 279.4 NCT01641809
- 254 vs 257.1 NCT01641809
- 266.1 vs 263.8 NCT01641809
- 259 vs 262.5 NCT01641809
- 212.3 vs 221.5 NCT01641809
- 265 vs 185.2 NCT01641809
- 209.9 vs 197.4 NCT01641809
- 193.3 vs 178.2 NCT01641809
- 194.7 vs 166.4 NCT01641809
- 204 vs 143.4 NCT01641809
- 269.4 vs 281.7 NCT01641809
- 261.5 vs 279.4 NCT01641809
- 232 vs 257.1 NCT01641809
- 217.7 vs 263.8 NCT01641809
- 235.1 vs 262.5 NCT01641809
- 203.6 vs 221.5 NCT01641809
- 192 vs 185.2 NCT01641809
- 191.4 vs 197.4 NCT01641809
- 205 vs 178.2 NCT01641809
- 186.4 vs 166.4 NCT01641809
- 172.5 vs 143.4 NCT01641809
- Elvitegravir
- 295 vs 273vs AtriplaNCT01095796
26 other results
- 60 vs 42 NCT01815736
- 274 vs 260 NCT01797445
- 285 vs 271 NCT01780506
- 205 vs 198 NCT00708162
- 61 vs 71 NCT01475838
- 83 vs 101 NCT01495702
- 256 vs 261 NCT01106586
- 239 vs 206 NCT01095796
- 321 vs 300 NCT01095796
- 225 vs 200 NCT01797445
- 221 vs 212 NCT01705574
- 235 vs 221 NCT01780506
- 323 vs 310 NCT01780506
- 138 vs 147 NCT00708162
- 56 vs 58 NCT01495702
- 280 vs 293 NCT01106586
- 360 vs 328 NCT01095796
- 56 vs -1 NCT02616783
- 40 vs 32 NCT01475838
- 207 vs 211 NCT01106586
- 338 vs 340 NCT01106586
- 48 vs -4 NCT02616783
- 177 vs 204 NCT01497899
- 240 vs 166 NCT00869557
- 165 vs 179 NCT01497899
- 161 vs 117 NCT00869557
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. Cabotegravir/rilpivirine (Cabenuva): 11 of 11 rows · Elvitegravir: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cabotegravir/rilpivirine (Cabenuva) Rows use multiple source trials | Elvitegravir Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 276 cells/uL @ 324wk30 mga,b,c,d,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses272 cells/uL @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 402 cells/uL @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 229 cells/uL @ 48wkb,c,d,e NCT01721109 · Phase 2/3 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log Maintenance | -2.89 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q4Wa,f,c NCT02120352 · Phase 2 · registry result, not featured evidence · combination show 1 more dose-2.77 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination | -2.26 vs -2.31 Raltegravir log @ 96wkf,c NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.215 log @ 324wk30 mga,b,c,d,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.438 log @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.488 log @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -3.16 log @ 48wkb,c,d,e NCT01721109 · Phase 2/3 · registry result, not featured evidence |
| HIV-1 RNA Ge50 Copies responder rate · % of participants No placebo or comparator arm | 2.2% (n=93) @ 12wk400 mg + 600 mg Q4Wc,d,g NCT05896748 · Phase 3 · registry result, not featured evidence · combination | 1.8% (n=223)a,c,d,g NCT02397096 · Phase 3 · registry result, not featured evidence show 1 more dose1.6% (n=447) NCT02397096 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA Less Than 400 Copies responder rate · % of participants Maintenance | 77% (n=60) vs 65% (n=62) Efavirenz @ 96wk30 mga,f,c,h NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses85% (n=61) vs 65% (n=62) Efavirenz @ 96wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 75% (n=60) vs 65% (n=62) Efavirenz @ 96wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 57% (n=351) vs 56.1% (n=351) Raltegravir @ 96wka,f,c,h NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 show 1 more dose61.3% (n=351) vs 63% (n=351) Raltegravir @ 96wk NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 87% (n=430) @ 52wkc,d,i NCT04399551 · Phase 3 · registry result, not featured evidence | 84.5% (n=278) @ 96wkc,d,i NCT01705574 · Phase 3 · registry result, not featured evidence 2 other source trials90.7% (n=73) @ 96wk NCT01363011 · Phase 3 · registry result, not featured evidence · combination 88.9% (n=33) @ 96wk NCT01363011 · Phase 3 · registry result, not featured evidence · combination |
| HIV-1 RNA LT 50 Copies responder rate · % of participants No placebo or comparator arm | 100% (n=115) @ 130wkc,d NCT04001803 · Phase 3 · registry result, not featured evidence | 94.6% (n=223)a,c,d NCT02397096 · Phase 3 · registry result, not featured evidence show 3 more doses94.6% (n=223) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence 90.8% (n=447) NCT02397096 · Phase 3 · registry result, not featured evidence 93.7% (n=447) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 13.6%j NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 8.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 13.1%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 6.5% NCT04399551 · Phase 3 · registry result, not featured evidence 11.3% NCT04001803 · Phase 3 · registry result, not featured evidence 1.3%CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 15.6%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 11.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 13.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 15.2%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 83.6%k NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results22.2% NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 6.3%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 20%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 16%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 43.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 12.3%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 12.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 10.2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.9%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 80.7% NCT01106586 · Phase 3 · registry result, not featured evidence 0% NCT01533259 · Phase 3 · registry result, not featured evidence 14% NCT01721109 · Phase 2/3 · registry result, not featured evidence 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 6.3% NCT00869557 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —j NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 5.7%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 3.5% NCT04399551 · Phase 3 · registry result, not featured evidence 4.3% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 1.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 1.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 4.9%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence —30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 2.5%k NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results— NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 0.4%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 1.6%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0.9%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 6.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 0.7%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 2.5% NCT01106586 · Phase 3 · registry result, not featured evidence — NCT01533259 · Phase 3 · registry result, not featured evidence — NCT01721109 · Phase 2/3 · registry result, not featured evidence 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence — NCT00869557 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%j NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 3.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 6.3%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence 3.4%Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 4% NCT04399551 · Phase 3 · registry result, not featured evidence 7.8% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 12.7%Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 10%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 26.5%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 11.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 0%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.4%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 17%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.1%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.6%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 15.2%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 12.5%Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03149848 · Phase 1 · registry result, not featured evidence 7.1%300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 19.8%k NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results0% NCT02477527 · Phase 4 · registry result, not featured evidence 1.9%DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 6.4%DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.5%DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 2.3%DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence 2.9%ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence 2.6%ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 9.3%ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.3%ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 3.6%ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 16.8%Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 20.6% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 15.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 18.2%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 8.2% NCT01475838 · Phase 3 · registry result, not featured evidence 8.9%All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.2%Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 16.4% NCT01106586 · Phase 3 · registry result, not featured evidence 2.1% NCT01533259 · Phase 3 · registry result, not featured evidence 10% NCT01721109 · Phase 2/3 · registry result, not featured evidence 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.2% NCT00869557 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | j injection site discomfort 13.6% injection site pain 13.6% fatigue 2.3% NCT04982445 · Phase 4 · registry result, not featured evidence show 40 more results400 mg + 600 mg Q4W injection site pain 32.3% injection site nodule 9.7% injection site induration 2.2% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 74.2% injection site nodule 64.5% injection site erythema 51.6% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 30.9% injection site nodule 3.2% injection site pruritus 2.1% NCT05896748 · Phase 3 · registry result, not featured evidence · combination injection site pain 65.2% covid-19 17.9% headache 12.5% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 60.6% covid-19 19.4% injection site induration 11.4% NCT04542070 · Phase 3 · registry result, not featured evidence Q2M injection site pain 37.9% covid-19 14.5% arthralgia 0% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 80.2% covid-19 18.4% injection site induration 11.2% NCT04399551 · Phase 3 · registry result, not featured evidence injection site pain 55.7% injection site discomfort 26.1% fatigue 20% NCT04001803 · Phase 3 · registry result, not featured evidence creatinine renal clearance decreased 19.7% lipase increased 11.3% chills 7% NCT03739996 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 99.1% injection site nodule 49.6% nasopharyngitis 47% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 80% injection site nodule 50% nasopharyngitis 50% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 96.5% nasopharyngitis 47% injection site nodule 40% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 91.2% injection site nodule 35.3% covid-19 26.5% NCT02120352 · Phase 2 · registry result, not featured evidence · combination Q2M injection site pain 74.4% covid-19 33.3% upper respiratory tract infection 17.8% NCT03639311 · Phase 2 · registry result, not featured evidence · combination 30 mg headache 21.7% nausea 18.3% upper respiratory tract infection 13.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 26.4% diarrhoea 13.2% rash 11.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 31.9% back pain 12.8% oropharyngeal pain 12.8% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg headache 21.3% diarrhoea 18% nausea 18% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 21.8% nausea 14.5% bronchitis 10.9% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 27.5% anxiety 11.8% sinusitis 11.8% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg nausea 23.3% headache 21.7% diarrhoea 16.7% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg upper respiratory tract infection 17.3% depression 9.6% diarrhoea 9.6% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg diarrhoea 13% nasopharyngitis 10.9% gonorrhoea 8.7% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg dizziness 37.5% (placebo 0%) dyspepsia 25% (placebo 0%) headache 25% (placebo 0%) NCT00920426 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain 0% (placebo 0%) abnormal dreams 0% (placebo 0%) blood bilirubin increased 0% (placebo 50%) NCT00920426 · Phase 2 · registry result, not featured evidence 30 mg atrioventricular block first degree 7.7% decreased appetite 7.7% headache 7.7% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% aspartate aminotransferase increased 50% blood creatine phosphokinase increased 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site nodule 55.6% injection site erythema 44.4% NCT04484337 · Phase 1 · registry result, not featured evidence injection site haemorrhage 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 72.7% injection site pain 72.7% injection site induration 45.5% NCT04484337 · Phase 1 · registry result, not featured evidence injection site induration 100% injection site pain 100% injection site bruising 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 75% headache 37.5% injection site swelling 37.5% NCT04484337 · Phase 1 · registry result, not featured evidence catheter site bruise 50% injection site erythema 50% injection site induration 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 94.4% headache 77.8% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 100% injection site pruritus 87.5% NCT04484337 · Phase 1 · registry result, not featured evidence · combination injection site erythema 100% injection site pain 100% injection site warmth 88.9% NCT04484337 · Phase 1 · registry result, not featured evidence · combination accident 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site swelling 70% headache 60% NCT04484337 · Phase 1 · registry result, not featured evidence 30 mg blood creatine phosphokinase increased 6.7% contusion 6.7% body temperature increased 0% NCT03149848 · Phase 1 · registry result, not featured evidence 300 mg + 30 mg body temperature increased 7.1% headache 7.1% hyperkeratosis 7.1% NCT03149848 · Phase 1 · registry result, not featured evidence · combination | k diarrhoea 26.7% upper respiratory tract infection 26.4% nausea 23% NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 31 more resultsheadache 6.7% diarrhoea 4.3% nasopharyngitis 4.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.4% headache 6.4% diarrhoea 5.4% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 3.9% headache 1.9% back pain 1.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% headache 6.5% diarrhoea 4.5% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.4% back pain 3.7% diarrhoea 3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.8% headache 5.5% arthralgia 5.3% NCT02397096 · Phase 3 · registry result, not featured evidence back pain 2.3% arthralgia 1.7% nasopharyngitis 1.7% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 8.3% arthralgia 1.2% diarrhoea 1.2% NCT02397096 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.4% nasopharyngitis 5.2% diarrhoea 4.4% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% diarrhoea 5.2% nasopharyngitis 4.7% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.5% diarrhoea 11.4% nasopharyngitis 10% NCT01815736 · Phase 3 · registry result, not featured evidence diarrhoea 23% headache 22.7% upper respiratory tract infection 20.2% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 3.5% headache 2.8% arthralgia 1.4% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% cough 2.5% syphilis 2.5% NCT01797445 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence diarrhoea 25.7% upper respiratory tract infection 21.1% nausea 16.8% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 cough 4.4% syphilis 4.4% upper respiratory tract infection 3.3% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 33.9% upper respiratory tract infection 21.2% headache 13.8% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 upper respiratory tract infection 20.5% nasopharyngitis 19.2% bronchitis 13.7% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 36.4% insomnia 21.2% headache 18.2% NCT01363011 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.3% upper respiratory tract infection 9.9% diarrhoea 9.2% NCT01475838 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.2% nasopharyngitis 10.2% NCT01495702 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.3% nasopharyngitis 10.3% NCT01495702 · Phase 3 · registry result, not featured evidence diarrhoea 28% upper respiratory tract infection 24.4% nausea 22.7% NCT01106586 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.8% insomnia 12.5% anxiety 10.4% NCT01533259 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 36% headache 24% vomiting 20% NCT01721109 · Phase 2/3 · registry result, not featured evidence nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 27.1% fatigue 16.7% headache 14.6% NCT00869557 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 2/3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 324 weeks versus 48 weeks.
- fTrial phases differ: Phase 2 versus Phase 3.
- gThe assessment timepoint is not available for both results.
- hTreatment context differs: pooled versus combination.
- iAssessment timepoints differ: 52 weeks versus 96 weeks.
- jPopulation comparability has not been reviewed for these studies.
- kPopulation comparability has not been reviewed for 34 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cabotegravir/rilpivirine (Cabenuva)
show 2 more results
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
+ 163 further endpoints in the CSV export.
Elvitegravir
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Elvitegravir's landscape